Figures Legends :
Figure 1: B cell response by Neutralizing IgG Antibodies in
Pediatric Cancer Patients compared to Healthy Controls. Quantitative
neutralizing antibody response at each time point after vaccination
compared to healthy controls. Please note that healthy controls only had
one time point and for optimal visualization, is presented in a linear
fashion over each time point (red line). A. Pediatric cancer
patients with adequate B cell response. B. Pediatric cancer
patients with inadequate B cell response.
Figure 2: Evaluation of clinical factors that may response to
SARS-COV2 vaccination . A . B cell response after vaccination in
leukemia/lymphoma patients (upper) and solid tumor patients
(lower). B. Comparison of absolute lymphocyte counts prior to
vaccination (0 week) and 8-12 weeks post vaccination in the adequate vs
inadequate response groups. There was no statistical significance
between any of the groups (Adequate response 0 wk and inadequate
response 0 wk, p = 0.86; Adequate response 8 wk and inadequate response
8 wk, p = 0.99; adequate response 0 wk and adequate response 8 wk, p =
0.75; inadequate response 0 wk and adequate response 8 wk, p = 0.79).C. B cell response after vaccination in patients with highly
myelosuppressive (upper) and less myelosuppressive (lower) chemotherapy.
There was no statistical difference in neutralizing antibodies between
both therapy groups (2 wk, p = 0.859; 4-6 wk, p = 0.740, 8-12 wk, p =
0.758).